JP Morgan Chase’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

JP Morgan Chase’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,000	Closed	-$185K	–	7476
2023 Q1	$185K	Buy	+8,000	New	+$191K	﹤0.01%	5111

JP Morgan Chase's KDNY Position: Q3 2023 in Review

JP Morgan Chase sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 283,819 shares — an estimated $10.9M sold.

JP Morgan Chase first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $10.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

JP Morgan Chase reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
JP Morgan Chase sold 283,819 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $10.9M.
JP Morgan Chase first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
JP Morgan Chase's Chinook Therapeutics, Inc. Common Stock position peaked at $10.9M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.